424 related articles for article (PubMed ID: 36410749)
21. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.
Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE
JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096
[TBL] [Abstract][Full Text] [Related]
22. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
Montgomery J; Ryan M; Engler R; Hoffman D; McClenathan B; Collins L; Loran D; Hrncir D; Herring K; Platzer M; Adams N; Sanou A; Cooper LT
JAMA Cardiol; 2021 Oct; 6(10):1202-1206. PubMed ID: 34185045
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide.
Straus W; Urdaneta V; Esposito DB; Mansi JA; Sanz Rodriguez C; Burton P; Vega JM
Clin Infect Dis; 2023 Feb; 76(3):e544-e552. PubMed ID: 35666513
[TBL] [Abstract][Full Text] [Related]
24. COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis.
Kim J; Kwon HY; Ahn SJ
JAMA Ophthalmol; 2024 Jun; 142(6):522-528. PubMed ID: 38662361
[TBL] [Abstract][Full Text] [Related]
25. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
[TBL] [Abstract][Full Text] [Related]
26. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP
Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
28. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans.
Dickerman BA; Madenci AL; Gerlovin H; Kurgansky KE; Wise JK; Figueroa Muñiz MJ; Ferolito BR; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA
JAMA Intern Med; 2022 Jul; 182(7):739-746. PubMed ID: 35696161
[TBL] [Abstract][Full Text] [Related]
29. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
Mevorach D; Anis E; Cedar N; Bromberg M; Haas EJ; Nadir E; Olsha-Castell S; Arad D; Hasin T; Levi N; Asleh R; Amir O; Meir K; Cohen D; Dichtiar R; Novick D; Hershkovitz Y; Dagan R; Leitersdorf I; Ben-Ami R; Miskin I; Saliba W; Muhsen K; Levi Y; Green MS; Keinan-Boker L; Alroy-Preis S
N Engl J Med; 2021 Dec; 385(23):2140-2149. PubMed ID: 34614328
[TBL] [Abstract][Full Text] [Related]
30. Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.
Singh RB; Parmar UPS; Ichhpujani P; Jeng BH; Jhanji V
Cornea; 2023 Jun; 42(6):731-738. PubMed ID: 36706232
[TBL] [Abstract][Full Text] [Related]
31. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
32. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S
JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110
[TBL] [Abstract][Full Text] [Related]
33. Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
Guo BQ; Li HB; Yang LQ
Vaccine; 2023 Jun; 41(28):4067-4080. PubMed ID: 37246067
[TBL] [Abstract][Full Text] [Related]
34. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
[TBL] [Abstract][Full Text] [Related]
35. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
36. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination.
Kim HW; Jenista ER; Wendell DC; Azevedo CF; Campbell MJ; Darty SN; Parker MA; Kim RJ
JAMA Cardiol; 2021 Oct; 6(10):1196-1201. PubMed ID: 34185046
[TBL] [Abstract][Full Text] [Related]
37. Global reports of myocarditis following COVID-19 vaccination: A systematic review and meta-analysis.
Ahmed SK; Mohamed MG; Essa RA; Ahmed Rashad EA; Ibrahim PK; Khdir AA; Wsu ZH
Diabetes Metab Syndr; 2022 Jun; 16(6):102513. PubMed ID: 35660931
[TBL] [Abstract][Full Text] [Related]
38. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
[TBL] [Abstract][Full Text] [Related]
39. Risks of Myocarditis and Pericarditis Following Vaccination with SARS-CoV-2 mRNA Vaccines in Japan: An Analysis of Spontaneous Reports of Suspected Adverse Events.
Kobayashi H; Fukuda S; Matsukawa R; Asakura Y; Kanno Y; Hatta T; Saito Y; Shimizu Y; Kawarasaki S; Kihara M; Kinoshita N; Umeda H; Noda T; Imamura T; Nishioka Y; Yamaguchi T; Hayashi S; Iguchi T
Ther Innov Regul Sci; 2023 Mar; 57(2):329-342. PubMed ID: 36310329
[TBL] [Abstract][Full Text] [Related]
40. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study.
Kildegaard H; Lund LC; Højlund M; Stensballe LG; Pottegård A
BMJ; 2022 Apr; 377():e068898. PubMed ID: 35410884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
